A case report of atypical Kawasaki disease presented with severe elevated transaminases and literature review

BMC Infect Dis. 2021 May 4;21(1):415. doi: 10.1186/s12879-021-06101-y.

Abstract

Background: Kawasaki disease (KD) is the most common cause of acquired heart disease among children in developed countries, in which the resulting coronary artery (CA) abnormalities cause myocardial ischemia, infarction, and death. Prompt diagnosis was essential, and supplemental information should be used to assist the diagnosis when classical clinical criteria are incomplete. The elevated levels of serum transaminases in most KD patients are mild. Herein, a case of atypical KD child with severely elevated transaminase was reported.

Case presentation: A child with clinical manifestations of fever, high C-reactive protein (CRP) and severely elevated transaminases was reported. The treatment effect of antibiotic and liver-protecting drugs was not satisfactory. A bilateral diffuse dilation of the CA was detected on echocardiography on day 5 of the illness; thus, atypical KD was diagnosed. Elevated transaminases declined rapidly to normal after the treatment of intravenous immunoglobulin (IVIG). A 1-month follow-up revealed that CA returned to normal, and 2-month, 6-months, and 1-year follow-up revealed the child was in good general health.

Conclusions: This case highlighted that atypical KD clinical symptoms were diverse, and severely elevated transaminases might provide a clue to healthcare providers for the diagnosis and management of atypical KD.

Keywords: Atypical Kawasaki disease; Case report; Children; Kawasaki disease; Severely elevated transaminases.

Publication types

  • Case Reports
  • Review

MeSH terms

  • C-Reactive Protein / analysis
  • Coronary Vessels / diagnostic imaging
  • Coronary Vessels / physiopathology
  • Echocardiography
  • Fever / drug therapy
  • Fever / etiology
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Infant
  • Male
  • Mucocutaneous Lymph Node Syndrome / drug therapy*
  • Mucocutaneous Lymph Node Syndrome / etiology*
  • Transaminases / blood*

Substances

  • Immunoglobulins, Intravenous
  • C-Reactive Protein
  • Transaminases